Comparison of Two Sulfonylureas with High and Low Myocardial K(ATP) Channel Affinity on Myocardial Infarct Size and Metabolism in a Rat Model of Type 2 Diabetes

Overview

Journal Diabetologia

Specialty Endocrinology

Date 2010 Nov 25

PMID 21104069

Citations 8

Authors

S B Kristiansen

B Lofgren

J M Nielsen

N B Stottrup

E S Buhl

J E Nielsen-Kudsk

T T Nielsen

J Rungby

A Flyvbjerg

H E Botker

Affiliations

Soon will be listed here.

Abstract

Aims/hypothesis: Sulfonylureas (SUs) may impair outcome in patients with acute coronary syndrome. Most experimental studies of the myocardial effects of SU treatment are performed in non-diabetic models. We compared the effect of two widely used SUs, glibenclamide (gb) and gliclazide (gc), with high and low myocardial K(ATP) channel affinity, respectively, at therapeutic concentrations on infarct size, left ventricular (LV) function and myocardial glycogen, lactate and alanine content before and after ischaemia/reperfusion (I/R).

Methods: Non-diabetic Wistar and diabetic Goto-Kakizaki rat hearts were investigated in a Langendorff preparation. Gb (0.1 μmol/l) and gc (1.0 μmol/l) were administrated throughout the study. Infarct size was evaluated after 120 min of reperfusion. Myocardial metabolite content was measured before and after ischaemia.

Results: Infarct size was smaller in diabetic hearts than in non-diabetic hearts (0.33 ± 0.03 vs 0.51 ± 0.05, p < 0.05). Gb increased infarct size (0.54 ± 0.04 vs 0.33 ± 0.03, p < 0.05) and reduced post-ischaemic LV developed pressure (60 ± 3 vs 76 ± 3 mmHg, p < 0.05) and coronary flow (4.9 ± 0.5 vs 7.1 ± 0.4 ml min(-1) g(-1), p < 0.05) in gb-treated diabetic rats compared with untreated diabetic rats. On comparing gb-treated diabetic rats with untreated diabetic rats, glycogen content was reduced before (9.1 ± 0.6 vs 13.6 ± 1.0 nmol/mg wet weight, p < 0.01) and after ischaemia (0.9 ± 0.2 vs 1.8 ± 0.2 nmol/mg wet weight, p < 0.05), and lactate (4.8 ± 0.4 vs 3.2 ± 0.3 nmol/mg wet weight, p < 0.01) and alanine (1.38 ± 0.12 vs 0.96 ± 0.09 nmol/mg wet weight, p < 0.05) contents were increased during reperfusion. Gc-treatment of diabetic and non-diabetic rats did not affect any of the measured variables.

Conclusions/interpretations: Gb, but not gc, exacerbates I/R injury and deteriorates LV function in diabetic hearts. These effects of gb on diabetic hearts may be due to detrimental effects on myocardial carbohydrate metabolism.

Citing Articles

Myocardial remote ischemic preconditioning: from cell biology to clinical application.

Donato M, Bin E, D Annunzio V, Gelpi R Mol Cell Biochem. 2021; 476(10):3857-3867.

PMID: 34125317 DOI: 10.1007/s11010-021-04192-4.

Sexual dimorphism in vascular ATP-sensitive K channel function supporting interstitial via convective and/or diffusive O transport.

Colburn T, Weber R, Schulze K, Hageman K, Horn A, Behnke B J Physiol. 2021; 599(13):3279-3293.

PMID: 34101850 PMC: 8451062. DOI: 10.1113/JP281120.

Vascular ATP-sensitive K channels support maximal aerobic capacity and critical speed via convective and diffusive O transport.

Colburn T, Weber R, Hageman K, Caldwell J, Schulze K, Ade C J Physiol. 2020; 598(21):4843-4858.

PMID: 32798233 PMC: 7874302. DOI: 10.1113/JP280232.

Co-morbidities and co-medications as confounders of cardioprotection-Does it matter in the clinical setting?.

Kleinbongard P, Botker H, Ovize M, Hausenloy D, Heusch G Br J Pharmacol. 2019; 177(23):5252-5269.

PMID: 31430831 PMC: 7680006. DOI: 10.1111/bph.14839.

Impact of hyperglycemia on myocardial ischemia-reperfusion susceptibility and ischemic preconditioning in hearts from rats with type 2 diabetes.

Kristiansen S, Paelestik K, Johnsen J, Jespersen N, Pryds K, Hjortbak M Cardiovasc Diabetol. 2019; 18(1):66.

PMID: 31151453 PMC: 6543682. DOI: 10.1186/s12933-019-0872-7.

References

Sato T, Nishida H, Miyazaki M, Nakaya H . Effects of sulfonylureas on mitochondrial ATP-sensitive K+ channels in cardiac myocytes: implications for sulfonylurea controversy. Diabetes Metab Res Rev. 2006; 22(5):341-7. DOI: 10.1002/dmrr.621. View

Takahashi N, Ooie T, Saikawa T, Iwao T, Yoshimatsu H, Sakata T . Long-term treatment with glibenclamide increases susceptibility of streptozotocin-induced diabetic rat heart to reperfusion-induced ventricular tachycardia. Exp Biol Med (Maywood). 2003; 228(10):1234-8. DOI: 10.1177/153537020322801021. View

Inoue I, Nagase H, Kishi K, Higuti T . ATP-sensitive K+ channel in the mitochondrial inner membrane. Nature. 1991; 352(6332):244-7. DOI: 10.1038/352244a0. View

Engbersen R, Masereeuw R, van Gestel M, van der Logt E, Smits P, Russel F . Glibenclamide depletes ATP in renal proximal tubular cells by interfering with mitochondrial metabolism. Br J Pharmacol. 2005; 145(8):1069-75. PMC: 1576225. DOI: 10.1038/sj.bjp.0706275. View

Gribble F, Tucker S, Seino S, Ashcroft F . Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels. Diabetes. 1998; 47(9):1412-8. DOI: 10.2337/diabetes.47.9.1412. View

Lofgren B, Povlsen J, Rasmussen L, Stottrup N, Solskov L, Krarup P . Amino acid transamination is crucial for ischaemic cardioprotection in normal and preconditioned isolated rat hearts--focus on L-glutamate. Exp Physiol. 2009; 95(1):140-52. DOI: 10.1113/expphysiol.2009.049452. View

Sartor G, Melander A, SCHERSTEN B . Serum glibenclamide in diabetic patients, and influence of food on the kinetics and effects of glibenclamide. Diabetologia. 1980; 18(1):17-22. DOI: 10.1007/BF01228296. View

Kristiansen S, Lofgren B, Stottrup N, Khatir D, Nielsen-Kudsk J, Nielsen T . Ischaemic preconditioning does not protect the heart in obese and lean animal models of type 2 diabetes. Diabetologia. 2004; 47(10):1716-21. DOI: 10.1007/s00125-004-1514-4. View

Leibowitz G, Cerasi E . Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing?. Diabetologia. 1996; 39(5):503-14. DOI: 10.1007/BF00403296. View

10.

Johnsen S, Monster T, Olsen M, Thisted H, McLaughlin J, Sorensen H . Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs. Am J Ther. 2006; 13(2):134-40. DOI: 10.1097/00045391-200603000-00009. View

11.

Mazumder P, ONeill B, Roberts M, Buchanan J, Yun U, Cooksey R . Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes. 2004; 53(9):2366-74. DOI: 10.2337/diabetes.53.9.2366. View

12.

Garratt K, Brady P, Hassinger N, Grill D, Terzic A, Holmes Jr D . Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol. 1999; 33(1):119-24. DOI: 10.1016/s0735-1097(98)00557-9. View

13.

Safer B . The Metabolic Significance of the Malate-Aspartate Cycle in Heart. Circ Res. 1975; 37(5):527-33. DOI: 10.1161/01.res.37.5.527. View

14.

Palmer K, Brogden R . Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. Drugs. 1993; 46(1):92-125. DOI: 10.2165/00003495-199346010-00007. View

15.

Povlsen J, Lofgren B, Rasmussen L, Nielsen J, Norregaard R, Kristiansen S . Cardioprotective effect of L-glutamate in obese type 2 diabetic Zucker fatty rats. Clin Exp Pharmacol Physiol. 2009; 36(9):892-8. DOI: 10.1111/j.1440-1681.2009.05166.x. View

16.

McPherson C, Pierce G, Cole W . Ischemic cardioprotection by ATP-sensitive K+ channels involves high-energy phosphate preservation. Am J Physiol. 1993; 265(5 Pt 2):H1809-18. DOI: 10.1152/ajpheart.1993.265.5.H1809. View

17.

Lawrence C, Proks P, Rodrigo G, Jones P, Hayabuchi Y, Standen N . Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells. Diabetologia. 2001; 44(8):1019-25. DOI: 10.1007/s001250100595. View

18.

Shimabukuro M, Nagamine F, Murakami K, Oshiro K, MIMURA G . Chronic gliclazide treatment affects basal and post-ischemic cardiac function in diabetic rats. Gen Pharmacol. 1994; 25(4):697-704. DOI: 10.1016/0306-3623(94)90248-8. View

19.

Grover G, Newburger J, Sleph P, Dzwonczyk S, Taylor S, AHMED S . Cardioprotective effects of the potassium channel opener cromakalim: stereoselectivity and effects on myocardial adenine nucleotides. J Pharmacol Exp Ther. 1991; 257(1):156-62. View

20.

Matsumoto S, Cho S, Tosaka S, Ureshino H, Maekawa T, Hara T . Pharmacological preconditioning in type 2 diabetic rat hearts: the roles of mitochondrial ATP-sensitive potassium channels and the phosphatidylinositol 3-kinase-Akt pathway. Cardiovasc Drugs Ther. 2009; 23(4):263-70. DOI: 10.1007/s10557-009-6184-5. View